IDEXX Laboratories SEC Filings

Jonathan Jay Mazelsky, who is reported as a Director and the President and CEO of IDEXX Laboratories, reported an insider transaction involving common stock and a related option. The Form 4 shows an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share, with reported beneficial ownership following the transaction of 83,494.3016 shares (direct).

The filing also discloses a Premium Incentive Stock Option tied to 183 underlying shares with an exercise/conversion price of $598.488. The explanatory note states the option was granted at a 110% premium to the closing price on February 12, 2021 and became exercisable in one installment on February 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Mazelsky.

Andrew Emerson, EVP, CFO and Treasurer of IDEXX Laboratories (IDXX), reported insider transactions dated 08/07/2025. The filing shows an acquisition of 1,849 common shares at $141.60 and a disposition of 402 common shares at $650.06. Following the reported transactions, beneficial ownership is shown as 4,272.778 shares (direct) after the acquisition and 3,870.778 shares (direct) after the disposition. The filing notes 27.3420 shares purchased under the employee stock purchase plan on March 31, 2025 and June 30, 2025, and references a grant of an option to buy 1,849 shares that vested on February 14, 2022. The form is signed by an attorney-in-fact on 08/11/2025.

Idexx Laboratories insider transaction disclosed via Form 144. The filing reports a proposed sale of 1,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $787,840.20. The shares were acquired by exercise on 08/06/2025 and payment was made in cash. With 80,004,694 shares outstanding, the proposed sale represents approximately 0.0015% of the company’s outstanding common stock.

The filing also lists three sales by NIMRATA K HUNT on 08/06/2025 totaling 7,143 shares and gross proceeds of $4,503,160.86. The filer affirms they are not aware of any material nonpublic adverse information about the issuer.

Idexx Laboratories executive Nimrata Hunt reported option exercises and market sales on 08/06/2025. The filing shows conversion of non-qualified stock options into common stock for 1,218, 5,865 and 5,711 shares at strikes of $141.60, $178.26 and $206.94 respectively, and three open-market sales totaling 7,143 shares at prices between $630.6891 and $630.9087. The reporting person owned 25,149.9435 shares before the sales and owned 18,006.9435 shares directly after the transactions, with an additional 160 shares held indirectly (jointly with spouse). The Form documents the mechanics of option-to-share conversion and subsequent sales without stating motives.

Jonathan Jay Mazelsky, President and CEO and a director of IDEXX Laboratories (IDXX), reported a series of transactions dated 08/06/2025. He acquired 29,260 shares by exercising non-qualified stock options at an exercise price of $67.85 per share and sold a matching total of 29,260 common shares the same day in multiple tranches at reported weighted-average prices between $626.9024 and $639.3718 per share. The reported sales reduced his direct holdings from 112,571.3016 shares to 83,311.3016 shares. Based on the reported quantities and prices, the aggregate gross proceeds from the sales are approximately $18.49 million. The filing also references an option grant to buy 41,260 shares that became exercisable in five annual installments beginning 02/14/2017.

Michael Lane, Executive Vice President of Idexx Laboratories (IDXX), reported multiple stock and option transactions dated 08/06/2025. The filing shows acquisitions of 1,286 and 7,125 shares (prices listed as $206.94 and $288.78), and dispositions of 5,631, 2,480 and 300 shares at weighted-average prices of $627.5634, $627.9911 and $628.8866, respectively. After these transactions the filing reports total direct beneficial ownership of 7,131.9435 shares and an additional 592 shares held indirectly by the reporting person’s spouse in an IRA.

The filing also lists non-qualified stock option awards related to the reporting person: a right associated with 1,286 underlying shares (exercise price $206.94) and a right associated with 7,125 underlying shares (exercise price $288.78). Explanations note prior grants exercisable in installments beginning in 2020 and 2021 and purchases of 28.7090 shares under the issuer’s Employee Stock Purchase Plan.

IDEXX Laboratories Inc. filed a Form 144 to register the proposed sale of 5,450 shares of common stock, with an aggregate market value of $3,551,220.00, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC. The filing lists 80,004,694 shares outstanding and shows an approximate sale date of 08/08/2025.

The shares were acquired via a stock option exercise on 08/08/2025 and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months and includes the standard attestation about material nonpublic information and trading-plan language. The provided content does not show a populated notice date or signature block.

Form 144 summary for IDEXX Laboratories, Inc. (IDXX)

This Form 144 reports a proposed sale of 7,143 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $4,503,160.87. Shares outstanding are listed as 80,004,694. The approximate date of sale is 08/06/2025.

The securities were acquired by stock option exercise on 08/06/2025 from the issuer and payment is listed as cash. The filing states "Nothing to Report" for securities sold during the past three months. Several filer and issuer contact fields (CIK, submission contact name/phone/email, date of notice, signature) are not provided in the extract.